... REINACH Switzerland November 27 /- Arpida... In the context of the FDA advisory board's recommendation the Arpi... Arpida will now thoroughly analyse the situation with external exp... We were very surprised by this very clear negative ruling by the ...

REINACH, Switzerland, November 27 /PRNewswire-FirstCall/ -- Arpida
announced today that it is refocusing all projects and priorities around the
key strategic asset Iclaprim. The company says this is to be seen as a
consequence of the negative recommendation of the U.S. Food and Drug
Administration (FDA) advisory board on 20 November 2008 regarding the
approval of Iclaprim in the U.S.

In the context of the FDA advisory board's recommendation the Arpida
board intends to put the company back on a firm footing through cutting costs
considerably. To achieve this, the company views the reduction of the
workforce by up to 60 employees as inevitable. A consultation process with
all employees has been initiated and will lead to decisions by the Board of
Directors which will be communicated on 16 December 2008. Board and
Management sincerely regret this measure and would like to point out that the
company will endeavour to fully assume its social responsibilities. Contact
with public authorities on this issue has been established and a social plan
will be presented in time.

Arpida will now thoroughly analyse the situation with external experts to
determine the future development of Iclaprim. Basis for this analysis will be
the full FDA response to the Iclaprim dossier and the publication of the
phase II oral step down therapy trial.

"We were very surprised by this very clear negative ruling by the FDA
advisory board", CEO Jurgen Raths said. "In particular we are very upset by
the steps we are forced to take in regards to our staff. The advisory board's
recommendation has come totally unexpected, because we are still convinced
that Iclaprim offers a valuable therapeutic asset for the treatment of
complicated skin and skin structure infections (cSSSI), especially where MRSA
(resistant bacteria called methicillin-resistant staphylococcus aureus) are
involved. We will use the FDA's feedback as well as further clinical advice
and expertise in our development decisions. We will also continue to
cooperate closely with the regulatory agencies in the U.S., Canada and Europe
to obtain market authorization for what we think is a valuable asset in the
fight against potentially life threatening infections."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in
Reinach, Switzerland with operations in Switzerland and the USA. It focuses
on the discovery, development and commercialisation of novel drugs that seek
to overcome the growing problem of microbial resistance. The most advanced
compounds include an antibacterial under regulatory review and an antifungal
in Phase III.

This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and unknown
risks, uncertainties and other factors which may result in a substantial
divergence between the actual results, financial situation, development or
performance of the company and those explicitly or implicitly presumed in
these statements. Against the background of these uncertainties readers
should not place undue reliance on forward-looking statements. The company
assumes no responsibility to update forward-looking statements or to adapt
them to future events or developments.

(Date:12/8/2016)... 8, 2016 Biotheranostics today announced that new ... the Breast Cancer Index (BCI) in identifying which ... most at-risk for disease recurrence and might benefit ... three studies advancing the understanding of the value ... biology and inform decisions related to patient treatment. ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...